Short Summary
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
Detailed Summary
AZURITY PHARMACEUTICALS, INC., the Petitioner, successfully obtained institution of IPR proceedings against Helsinn Healthcare S.A.'s patent (9186357) covering anti-emetic agents used in oncology treatment. The Board determined that the Petitioner demonstrated a reasonable likelihood that at least one challenged claim would be unpatentable over the prior art of record, primarily under 35 U.S.C. § 103. Key arguments centered on Herrstedt teaching a relevant triple-drug regimen and Bös providing motivation to substitute specific compounds within that regimen. The decision signals a strong challenge to the patent's validity based on obviousness in this specialized pharmaceutical field.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in AZURITY PHARMACEUTICALS, INC. vs Helsinn Healthcare S.A. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
The Integration Group of America, Inc.vsSitePro, Inc.
The Integration Group of America, Inc. filed a petition challenging SitePro, Inc.'s patent (9342078) on grounds of anticipation and obviousness over prior art including Almadi, Gutierrez, and SCADA. The petitioner argues that the challenged claims are fully disclosed by these references in the field of Industrial Automation.
Element TV Company, LP et al.vsNokia Technologies Oy
Element TV and Nokia have reached a settlement and jointly request that the Board treat the settlement agreement as confidential, moving to terminate the IPR over Nokia’s video broadcast patent.
Apple Inc.vsApex Beam Technologies LLC
Apple Inc. has filed an IPR petition challenging all 20 claims of Apex Beam’s ’904 patent covering multi‑antenna transmission. The petitioner asserts the claims are obvious over the Kim and Chen disclosures and seeks institution of the review.
MWE Investments, LLC et al.vsChampion Power Equipment, Inc.
MWE Investments, Harbor Freight and Generac have filed an IPR petition seeking cancellation of Champion Power Equipment’s dual‑fuel lockout switch patent, arguing that the claims are obvious or anticipated over multiple prior‑art references and that key claim terms lack proper structure.
Nintendo Co., Ltd. et al.vsMalikie Innovations Ltd.
Nintendo has filed an IPR petition seeking to invalidate six claims of Malikie Innovations' handheld directional‑input patent, arguing obviousness over a suite of prior‑art references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.